SBMFF (Sino Biopharmaceutical) Common Stock : $57 Mil (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Common Stock?

Sino Biopharmaceutical's quarterly common stock increased from Jun. 2023 ($58 Mil) to Dec. 2023 ($58 Mil) but then declined from Dec. 2023 ($58 Mil) to Jun. 2024 ($57 Mil).

Sino Biopharmaceutical's annual common stock declined from Dec. 2021 ($65 Mil) to Dec. 2022 ($60 Mil) and declined from Dec. 2022 ($60 Mil) to Dec. 2023 ($58 Mil).

Sino Biopharmaceutical Common Stock Historical Data

The historical data trend for Sino Biopharmaceutical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Common Stock Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

63.60

65.23

59.51

58.07

56.92

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial															59.51	57.90	58.07	57.12	56.92

Sino Biopharmaceutical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.